Long-term results of medical treatment in benign prostatic hyperplasia
In real-life clinical practice, we determined the incidence of acute urinary retention (AUR) and benign prostatic hyperplasia (BPH)-related surgery in patients with BPH who received alpha-adrenergic receptor blocker (α-blocker) and/or 5-alpha-reductase inhibitor combination treatment. This retrospec...
Saved in:
Published in | Urology (Ridgewood, N.J.) Vol. 68; no. 5; pp. 1015 - 1019 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Elsevier Inc
01.11.2006
Elsevier Science |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | In real-life clinical practice, we determined the incidence of acute urinary retention (AUR) and benign prostatic hyperplasia (BPH)-related surgery in patients with BPH who received alpha-adrenergic receptor blocker (α-blocker) and/or 5-alpha-reductase inhibitor combination treatment.
This retrospective study enrolled 341 patients with BPH who were prescribed an α-blocker and/or a 5-alpha-reductase inhibitor as their first treatment from January 1997 to June 1999. Using follow-up data from a 6 to 8-year period, we calculated the incidence of AUR and BPH-related surgery in the α-blocker-only group and in the combination group.
Of the 341 patients, 192 were in the α-blocker group and 149 were in the combination group. Of these, 17.7% in the α-blocker group and 12.1% in the combination group experienced AUR (
P <0.05). BPH-related surgery was performed in 10.9% of the α-blocker-only group and 6.0% of the combination group (
P <0.05). The incidence of AUR and BPH-related surgery was reduced by 32.3% and 48.9% when the prostate volume was larger than 35 g and by 49.4% and 60.6% when the prostate-specific antigen level was greater than 2.0 ng/mL, respectively, in the combination group compared with the corresponding values in the α-blocker group.
Real-life clinical practice showed that long-term combination treatment with α-blockers and 5-alpha-reductase inhibitors reduced the risk of BPH progression, such as AUR or BPH-related surgery, compared with α-blocker-only treatment. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0090-4295 1527-9995 |
DOI: | 10.1016/j.urology.2006.06.003 |